A randomized, double-blind, placebo-controlled dose-escalation Phase I study evaluating safety, tolerability and pharmacokinetics of inhaled single doses of POL6014 in healthy volunteers

Trial Profile

A randomized, double-blind, placebo-controlled dose-escalation Phase I study evaluating safety, tolerability and pharmacokinetics of inhaled single doses of POL6014 in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs POL 6014 (Primary)
  • Indications Alpha 1-antitrypsin deficiency; Cystic fibrosis
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Most Recent Events

    • 11 Apr 2017 New trial record
    • 01 Sep 2015 Accoprding to a Polyphor media release, company has announced initiation of recruitment in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top